Navigation Links
Schering-Plough Reports Top-Line Results of the IDEAL Study
Date:1/14/2008

uations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many, but not all cases, these disorders resolve after stopping PEGINTRON and/or INTRON A therapy.

Use with Ribavirin: Ribavirin may cause birth defects and/or death of the unborn child. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with REBETOL therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen

Contraindications

PEGINTRON is contraindicated in patients with hypersensitivity to PEGINTRON or any other component of the product, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6 [class B and C]) in cirrhotic CHC patients before or during treatment. INTRON A (Interferon alfa- 2b, recombinant) for Injection is contraindicated in patients with hypersensitivity to INTRON A or any component of the product, autoimmune hepatitis, and decompensated liver disease. PEGINTRON or INTRON A in combination with REBETOL therapy is additionally contraindicated in patients with hypersensitivity to ribavirin or any other component of the product, women who are pregnant, men whose female partners are pregnant, patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia), and patients with creatinine clearance less than 50 mL/min.

Avoid Pregnancy

REBETOL therapy should not be started until a report of a negative pregnancy test has been obtained immediately prior to planned initiation of therapy. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients during therapy and 6 months post- treatment. Patients should use at least two effective forms of contraception and have monthly pregnancy tests during therapy and for 6 months after
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
2. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
3. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
4. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
5. Second Thoughts about Fluoride, Reports Scientific American
6. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
7. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
8. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
9. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
10. Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM)
11. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 2013  Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical ... unique technology to deter prescription drug abuse today ... Anthony Soscia , has been chosen as ... ,s Health-Care Heroes Awards. The awards are presented ... to honor individuals and organizations demonstrating excellence and deserving ...
(Date:5/20/2013)... SAN DIEGO , May 20, 2013 ... in Elcelyx Therapeutics, Phase 2b dose-finding clinical trial of ... generic metformin, the foundational treatment for Type 2 diabetes. ... the multicenter U.S. program in June. Results of the ... are expected in late summer, and the read-out for ...
(Date:5/20/2013)... , May 20, 2013  Neuralstem, Inc. (NYSE ... , MD, PhD, principal investigator, presented updated Phase ... cell (NSI-566) trial in the treatment of amyotrophic lateral ... disease) at the neuro diabetes special medical symposium in ... a talk called "Recent Therapeutic Advances in Stem Cell ...
Breaking Medicine Technology:Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
... 20, 2011 TheCarrot.com , a leading ... programs, announced the immediate availability of its new ... the University of California at San Francisco,s Smoking ... behavior modification methodology with TheCarrot.com,s award-winning online and ...
... BETHESDA, Md., Jan. 20, 2011 Spherix Incorporated ... biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; ... food, supplement, biotechnology and pharmaceutical companies, today announced that ... million of shares of its common stock and warrants ...
Cached Medicine Technology:TheCarrot.com Launches Quit Smoking Program 2TheCarrot.com Launches Quit Smoking Program 3Spherix Announces Registered Direct Offering of $2.77 Million 2Spherix Announces Registered Direct Offering of $2.77 Million 3
(Date:5/20/2013)... May 20, 2013 This summer, digital ... world will make the pilgrimage to San Diego, CA, ... Digital Health Summer Summit produced by Living ... unique forum to showcase the latest digital health innovations, ... and network with some of industry’s most brilliant thinkers ...
(Date:5/20/2013)... Dennis Thompson HealthDay Reporter , , MONDAY, May ... attention deficit-hyperactivity disorder (ADHD) are twice as likely to ... disorder when they were young, a new 30-year study ... tended to have a higher body-mass index (BMI) and ... the disorder. Socioeconomics made no difference; well-off or ...
(Date:5/20/2013)... Posterior fossa subdural hematoma (PFSDH) is a serious and ... But with appropriate treatment, there,s an excellent chance of ... reports a study in the May issue of ... Congress of Neurological Surgeons . The journal is published ... of Wolters Kluwer Health . , The results ...
(Date:5/20/2013)... Wolters Kluwer Health is pleased to announce ... journals won 13 ASHPE awards in 10 categories. ... publications for editorial, design, print and online award ... recognized year after year for delivering high-quality publications ... quality, depth, and impact," said Jayne Marks, Vice ...
(Date:5/20/2013)... Francisco, CA (PRWEB) May 20, 2013 ... health assistant at HealthBeat 2013. A mobile application called ... the time and effort it takes to arrange for ... Allie offers a unique combination of mobile technology and ... order to help people ensure their health care needs ...
Breaking Medicine News(10 mins):Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 2Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 3Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 4Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 2Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 3Health News:Study supports 'aggressive' treatment for posterior fossa hematoma in newborns 2Health News:Study supports 'aggressive' treatment for posterior fossa hematoma in newborns 3Health News:Wolters Kluwer Health receives 13 awards from the ASHPE 2Health News:Allayo Debuts Virtual Health Assistant At HealthBeat 2013 2
... Nutrisystem, Inc. (Nasdaq: NTRI ), a leading developer ... new multi-year alliance with the American Diabetes Association to ... public about the importance of weight loss for people ... Nutrisystem will support the Association,s efforts to fund both ...
... 26 CardioGenics Holdings Inc. (OTC Bulletin Board: JAGH) has ... change for the Company on the OTCBB will take place ... The new ticker symbol for "CardioGenics Holdings Inc." on ... the name and ticker symbol change that is scheduled to ...
... , WASHINGTON , Oct. 26 ... Karen Ignagni, President and CEO: , "A new government-run plan would ... down costs and improve quality. The American people want health ... that. , "The divisive debate about a government-run plan ...
... LAKE FOREST, Ill., Oct. 26 Akorn, Inc. (Nasdaq: AKRX ) will release third ... conference call on Tuesday, November 10, to discuss quarterly results followed by a Q&A session: , ... Akorn Third Quarter 2009 Conference Call, Date/Time: ... ...
... the impact of severe physical, psychosocial suffering, researchers say ... survivors of World War II, those who were potentially ... cancer, likely due to physical and mental stress, an ... compared cancer rates in more than 300,000 Israeli Jews ...
... spell trouble, study finds , MONDAY, Oct. 26 (HealthDay News) ... the risk of dangerous blood clots in veins, although that ... indicates. , The 10-year study found that bigger hips are ... women but not men, while a wider waistline was associated ...
Cached Medicine News:Health News:Nutrisystem and the American Diabetes Association Form a Strategic Alliance to Promote the Importance of Weight Loss for People With Type 2 Diabetes 2Health News:Nutrisystem and the American Diabetes Association Form a Strategic Alliance to Promote the Importance of Weight Loss for People With Type 2 Diabetes 3Health News:AHIP Statement on Government-Run Plan 2Health News:AHIP Statement on Government-Run Plan 3Health News:Exposure to Holocaust May Have Raised Cancer Risks 2Health News:Where You Put on Pounds May Influence Clot Risk 2
... CCR Medical's Articulating Tip Laryngoscopes ... in the Industry. The articulating ... by providing an improved view ... and Fiber Optic styles. We ...
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
... Medical's Articulating Tip Laryngoscopes are ... the Industry. The articulating tip ... providing an improved view of ... Fiber Optic styles. We guarantee ...
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
Medicine Products: